DIRS.INFO The most relevant business & tech news

☆ The Inflation Reduction Act Is Already Killing Potential Cures
▼ + stars: | 2022-11-04 | by ( Joe Grogan | ) www.wsj.com time to read: +1 min

It may take years before we can fully appreciate the impact of the Inflation Reduction Act on the pharmaceutical industry, but we’re already getting signs of the damage. In response, many have canceled drug-development programs, resulting in an unfortunate but predictable loss for patients nationwide. One poorly crafted provision is driving companies away from research into treating rare diseases. The company’s drug is currently marketed as treating only amyloidosis, and thus is exempt from Medicare’s price setting. If Alnylam proceeded with research into treating Stargardt, it would lose its exemption.

☆ Drugmakers Look to Limit Medicare’s New Power to Negotiate Lower Drug Prices
▼ + stars: | 2022-10-20 | by ( Jared S. Hopkins | ) www.wsj.com time to read: 1 min

Drugmakers are trying to blunt Medicare’s newfound power to negotiate medicine prices while coping with internal industry disputes and ebbing influence in Washington, D.C. Under the Inflation Reduction Act, Congress gave Medicare, the country’s biggest buyer of prescription drugs, the authority to negotiate how much it pays for certain high-price therapies, and to get rebates on treatments whose prices rise more than the rate of inflation.

But the Inflation Reduction Act, which represents about a third of the spending, was passed by Democrats alone. The White House is still pushing a more expansive child tax credit that was not included in the Inflation Reduction Act. Here’s a detailed look at what Mr. Biden wanted and what he got:Climate and Environment Proposed $722 billion Passed $509 billionOn climate, the Biden administration got much of what it wanted. Health Care Proposed $563 billion Passed $412 billionOn health care, there were some victories for the president — and much trimming. The family programs were eliminated largely because of concerns from Mr. Manchin about the overall size of what became the Inflation Reduction Act.

☆ What Is a Medicare Advantage Plan, and Should You Sign Up for One?
▼ + stars: | 2022-10-14 | by ( Alex Janin | Leslie Scism | ) www.wsj.com time to read: 1 min

The health-plan decisions you make when you become eligible at age 65 could have future health and financial implications. You’re about to be awash in ads for Medicare Advantage plans, the private alternative to traditional Medicare. Evaluating the options can be challenging, but there are steps you can follow to make the best decision for yourself. Medicare’s open enrollment period runs from Oct. 15 through Dec. 7. Sometimes called “Part C,” Medicare Advantage plans are offered by Medicare-approved private companies.

Search resuls for: "Medicare’s"

4 mentions found